Real-world use of novel β-lactams in immunologically vulnerable patients: insights from an Italian retrospective cohort
Abstract
Background and objectives: Multidrug-resistant gram-negative bacteria pose a significant global health threat, particularly among vulnerable populations, such as the elderly and immunocompromised patients. Novel β-lactam (NBL) antibiotics offer promising treatment options, but real-world evidence on their efficacy in these populations remains limited. To describe the use of NBLs in clinical practice, focusing on immunologically vulnerable patients, including those with immunosuppression due to underlying disease or immunosuppressive therapy, as well as elderly individuals. Clinical characteristics, outcomes and microbiological data were descriptively analysed.
Methods: This retrospective cohort study was conducted at two university hospitals in Milan, Italy, from 2019 to 2024. Adult patients receiving NBLs (cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam or meropenem/vaborbactam) were included. Immunologically vulnerable patients were identified by at least one of the following conditions: active oncological disease, solid organ transplantation, autoimmune or rheumatological disorder requiring immunosuppressive therapy, HIV infection or age >85 years. A descriptive analysis of clinical and microbiological data was performed, and the clinical course was described using clinical and biochemical parameters.
Results: Overall, 233 patients were included, 80 (34.3%) of whom were immunologically vulnerable; 308 NBL prescriptions were recorded.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 233 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.